In the I-SPY 2 neoadjuvant trial, phospho-EGFR (Y1068, Y1173, or Y992), HER2 total, phospho-HER2 (Y1248), and phospho-Shc (Y317) were associated with pCR and recognized as predictive biomarkers for neratinib treatment in patients with breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.